Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Ervogastat MR vs IR Formulations
NCT04044053Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ervogastat in Nonalcoholic steatohepatitis (NASH), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 48 hours, Time to Reach Maximum Observed Plasma Concentration at 48 hours and 2 more. Started Aug 2019; status: completed.
02
Drugs
ervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04044053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044053.